Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 5

Editorial Foreword || FREE PAPER ||

Authors Garry M Walsh

Published 15 November 2007 Volume 2007:3(5) Pages 705—706

Garry M Walsh

Asthmatic and Allergy Inflammation Group, School of Medicine, University of Aberdeen, UK

This issue of Therapeutics and Clinical Risk Management contains interesting reviews on rheumatoid arthritis (RA), ulcerative colitis (UC) and steroid-resistant asthma all of which are distressing chronic inflammatory conditions of unclear etiology...

Download Article [PDF] 

Readers of this article also read:

Tadalafil in the treatment of erectile dysfunction

Robert M Coward, Culley C Carson

Therapeutics and Clinical Risk Management 2008, 4:1315-1329

Published Date: 5 December 2008

Emergence of new oral antithrombotics: a critical appraisal of their clinical potential

Michael Rud Lassen, Volker Laux

Vascular Health and Risk Management 2008, 4:1373-1386

Published Date: 5 December 2008

Impact of Pharmaceutical Care interventions in the identification and resolution of drug-related problems and on quality of life in a group of elderly outpatients in Ribeirão Preto (SP), Brazil

Divaldo Pereira de Lyra Júnior, Nadir Kheir, Juliana Palma Abriata, Chiara Ermínia da Rocha, Cláudia Benedita dos Santos, et al

Therapeutics and Clinical Risk Management 2007, 3:989-998

Published Date: 15 January 2008

Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction

James G McMurray, Robert A Feldman, Stephen M Auerbach, Herb DeRiesthal, Neal Wilson et al

Therapeutics and Clinical Risk Management 2007, 3:975-981

Published Date: 15 January 2008

The use of dorzolamide versus other hypotensive agents to prevent glaucomatous progression

Savvas Diafas, Douglas G Day, Jeanette A Stewart, William C Stewart

Therapeutics and Clinical Risk Management 2007, 3:725-732

Published Date: 15 November 2007

Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy

Shimon Lecht, Simon Haroutiunian, Amnon Hoffman, Philip Lazarovici

Therapeutics and Clinical Risk Management 2007, 3:467-474

Published Date: 15 July 2007

Optimal timing for antihypertensive dosing: focus on valsartan

Ramón C Hermida, Diana E Ayala, Carlos Calvo

Therapeutics and Clinical Risk Management 2007, 3:119-131

Published Date: 15 March 2007